PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Objectives:
To determine maximum tolerated dose of farnesyl transferase inhibitor, SCH 66336, when
administered w TEMODAR®.
To characterize any toxicity associated w combo of farnesyl transferase inhibitor, SCH 66336,
& TEMODAR®.
To observe patients for clinical antitumor response when treated with combination of farnesyl
transferase inhibitor, SCH 66336, & TEMODAR®.
To assess pharmacokinetics of SCH 66336 for patients on & not on enzyme inducing
antiepileptic drugs.